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Background:
Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary
syndrome (ACS). In acute chest pain without ST-segment elevation, they are used to differentiate unstable angina from
non ST-segment elevation myocardial infarction (NSTEMI). Recently, troponin assays with higher analytical sensitivities
became available to enable the detection of minor myocardial damage and identify individuals at higher risk for ACS. As a
result of its high tissue-specificity, cardiac troponin T and I are cardio-specific, highly sensitive markers for myocardial
damage. The aim of this study was to evaluate the new higher sensitive troponin (T and I) in patients with stable angina
and acute chest pain without ST-segment elevation.
Materials and methods:
Sixty subjects (mean age : 65.5± 11 years), were included: 20 healthy controls, 20 patients with stable angina, 9 with
unstable angina (troponin-) and 18 patients with NSTEMI myocardial infarction (troponin+). The protocol was approved by
the ethic committee of the University of Liège (Belgium). High sensitive troponin T (hsTnT) determination was realized on
heparin plasma by electrochemiluminescence immunoassay on Modular E (Roche Diagnostic). Troponin I II (TnI II) is a
chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin-I in heparine plasma
on the ARCHITECT i System (Abbott Diagnostic). The lower detection limit of these assays was 0.005µg/L for hsTnT and
0.01µg/L for TnI II.
Stastistical analysis was performed using t test. P value <0.05 was considered significant.
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Results:
• HsTnT levels were 0.003(0.003, 0.004) [median baseline (1st, 3rd quartile)] ng/mL in controls (Ctrl), 0.0075 (0.00475,
0.014) ng/mL in stable angina (SA), 0.011(0.006, 0.012) ng/mL in unstable angina (UA) and 0.3715 (0.1795, 1.00725)
ng/mL in NSTEMI (Figure 1).
• TnI II levels were 0 (0, 0.001) ng/mL in Ctrl and in patients with SA, 0.07 (0.005, 0.014) ng/mL in UA and 1.4475
(0.0407, 2.656) ng/mL in NSTEMI (Figure 2).
• Graphs were performed using a logarithmic scale in order to be more clear.
• HsTnT and TnI II levels were significantly increased in NSTEMI as compared to control subjects, patients with stable
and unstable angina. TnI II levels were also increased in unstable angina as compared to controls.
Conclusion:
In our population, TnI II was more sensitive than hsTnT to detect minor myocardial damage in patients with unstable
angina as compared to controls.
Therefore, future studies will have to determine whether TnI II might contribute to better risk stratification and treatment
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